-
1
-
-
0036622942
-
Epidemiology and clinical aspects on hepatitis C
-
Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002; 55: 69-77.
-
(2002)
Jpn J Infect Dis
, vol.55
, pp. 69-77
-
-
Higuchi, M.1
Tanaka, E.2
Kiyosawa, K.3
-
2
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
3
-
-
0036293899
-
Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future
-
Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002; 62: 8-17.
-
(2002)
Oncology
, vol.62
, pp. 8-17
-
-
Yoshizawa, H.1
-
4
-
-
0029833829
-
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
-
Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-89.
-
(1996)
Hepatology
, vol.24
, pp. 778-789
-
-
Poynard, T.1
Leroy, V.2
Cohard, M.3
-
5
-
-
0032585237
-
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
-
Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Ther Group (IHIT) Lancet 1998; 352: 1426-32.
-
(1998)
International Hepatitis Interventional Ther Group (IHIT) Lancet
, vol.352
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
-
6
-
-
0035934568
-
Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
7
-
-
0029130333
-
Lactoferrin: Molecular structure and biological function
-
Lonnerdal B, Iyer S. Lactoferrin: Molecular structure and biological function. Annu Rev Nutr 1995; 15: 93-110.
-
(1995)
Annu Rev Nutr
, vol.15
, pp. 93-110
-
-
Lonnerdal, B.1
Iyer, S.2
-
8
-
-
0141918811
-
Lactoferrin - A multifunctional protein with antimicrobial properties
-
Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol 2003; 40: 395-405.
-
(2003)
Mol Immunol
, vol.40
, pp. 395-405
-
-
Farnaud, S.1
Evans, R.W.2
-
9
-
-
0038058813
-
Antibacterial and antiviral effects of milk proteins and derivatives thereof
-
Florisa R, Recio I, Berkhout B, Visser S. Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des 2003; 9: 1257-75.
-
(2003)
Curr Pharm Des
, vol.9
, pp. 1257-1275
-
-
Florisa, R.1
Recio, I.2
Berkhout, B.3
Visser, S.4
-
10
-
-
0030740063
-
Hepatitis C virus envelope proteins bind lactoferrin
-
Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997; 71: 5997-6002.
-
(1997)
J Virol
, vol.71
, pp. 5997-6002
-
-
Yi, M.1
Kaneko, S.2
Yu, D.Y.3
Murakami, S.4
-
11
-
-
0032540093
-
Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes
-
Ikeda M, Sugiyama K, Tanaka T et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 1998; 245: 549-53.
-
(1998)
Biochem Biophys Res Commun
, vol.245
, pp. 549-553
-
-
Ikeda, M.1
Sugiyama, K.2
Tanaka, T.3
-
12
-
-
0033956354
-
Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells
-
Ikeda M, Nozaki A, Sugiyama K et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 2000; 66: 51-63.
-
(2000)
Virus Res
, vol.66
, pp. 51-63
-
-
Ikeda, M.1
Nozaki, A.2
Sugiyama, K.3
-
13
-
-
0032962172
-
Lactoferrin inhibits hepatitis C: Virus viremia in patients with chronic hepatitis C: A pilot study
-
Tanaka K, Ikeda M, Nozaki A et al. Lactoferrin inhibits hepatitis C: virus viremia in patients with chronic hepatitis C: A pilot study. Jpn J Cancer Res 1999; 90: 367-71.
-
(1999)
Jpn J Cancer Res
, vol.90
, pp. 367-371
-
-
Tanaka, K.1
Ikeda, M.2
Nozaki, A.3
-
14
-
-
0036127867
-
Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b
-
Iwasa M, Kaito M, Ikoma J et al. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 2002; 97: 766-7.
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 766-767
-
-
Iwasa, M.1
Kaito, M.2
Ikoma, J.3
-
15
-
-
0036747346
-
Dose-response trial of lactoferrin in patients with chronic hepatitis C
-
Okada S, Tanaka K, Sato T et al. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 2002; 93: 1063-9.
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 1063-1069
-
-
Okada, S.1
Tanaka, K.2
Sato, T.3
-
16
-
-
84989530085
-
Significance of specific antibody assay for genotyping of hepatitis C virus
-
Tanaka T, Tsukiyama-Kohara K, Yamaguchi K et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
-
(1994)
Hepatology
, vol.19
, pp. 1347-1353
-
-
Tanaka, T.1
Tsukiyama-Kohara, K.2
Yamaguchi, K.3
-
17
-
-
0027459488
-
Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity
-
Simmonds P, McOmish F, Yap PL et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity. J General Virol 1993; 74: 661-8.
-
(1993)
J General Virol
, vol.74
, pp. 661-668
-
-
Simmonds, P.1
McOmish, F.2
Yap, P.L.3
-
18
-
-
0000702241
-
Criteria for the evaluation of the clinical effects of solid cancer chemotherapy
-
Japan Society for Cancer Therapy
-
Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993; 28: 101-30.
-
(1993)
J Jpn Soc Cancer Ther
, vol.28
, pp. 101-130
-
-
-
19
-
-
0018687930
-
A multiple testing procedure for clinical trials
-
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
-
(1979)
Biometrics
, vol.35
, pp. 549-556
-
-
O'Brien, P.C.1
Fleming, T.R.2
-
20
-
-
0026023387
-
Origin of intact lactoferrin and its DNA-binding fragments found in the urine of human milk-fed preterm infants. Evaluation by stable isotopic enrichment
-
Hutchens TW, Henry JF, Yip TT et al. Origin of intact lactoferrin and its DNA-binding fragments found in the urine of human milk-fed preterm infants. Evaluation by stable isotopic enrichment. Pediatr Res 1991; 29: 243-50.
-
(1991)
Pediatr Res
, vol.29
, pp. 243-250
-
-
Hutchens, T.W.1
Henry, J.F.2
Yip, T.T.3
-
21
-
-
4544243886
-
No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats
-
Wakabayashi H, Kuwata H, Yamauchi K, Teraguchi S, Tamura Y. No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci Biotechnol Biochem 2004; 68: 853-60.
-
(2004)
Biosci Biotechnol Biochem
, vol.68
, pp. 853-860
-
-
Wakabayashi, H.1
Kuwata, H.2
Yamauchi, K.3
Teraguchi, S.4
Tamura, Y.5
-
22
-
-
33646572848
-
Phase I trial of oral talactoferrin alfa in refractory solid tumors
-
Hayes TG, Falchook GF, Varadhachary GR et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006; 24: 233-40.
-
(2006)
Invest New Drugs
, vol.24
, pp. 233-240
-
-
Hayes, T.G.1
Falchook, G.F.2
Varadhachary, G.R.3
-
23
-
-
3342947834
-
Protection against infections by oral lactoferrin: Evaluation in animal models
-
Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y. Protection against infections by oral lactoferrin: Evaluation in animal models. Biometals 2004; 17: 231-4.
-
(2004)
Biometals
, vol.17
, pp. 231-234
-
-
Teraguchi, S.1
Wakabayashi, H.2
Kuwata, H.3
Yamauchi, K.4
Tamura, Y.5
-
24
-
-
4544351650
-
Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice
-
Wakabayashi H, Kurokawa M, Shin K, Teraguchi S, Tamura Y, Shiraki K. Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice. Biosci Biotechnol Biochem 2004; 68: 537-44.
-
(2004)
Biosci Biotechnol Biochem
, vol.68
, pp. 537-544
-
-
Wakabayashi, H.1
Kurokawa, M.2
Shin, K.3
Teraguchi, S.4
Tamura, Y.5
Shiraki, K.6
-
25
-
-
0034434232
-
Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium
-
Kuhara T, Iigo M, Itoh T et al. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 2000; 38: 192-9.
-
(2000)
Nutr Cancer
, vol.38
, pp. 192-199
-
-
Kuhara, T.1
Iigo, M.2
Itoh, T.3
-
26
-
-
0033767482
-
Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin
-
Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 2000; 91: 1022-7.
-
(2000)
Jpn J Cancer Res
, vol.91
, pp. 1022-1027
-
-
Wang, W.P.1
Iigo, M.2
Sato, J.3
Sekine, K.4
Adachi, I.5
Tsuda, H.6
-
27
-
-
3242882447
-
Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy
-
Varadhachary A, Wolf JS, Petrak K et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004; 111: 398-403.
-
(2004)
Int J Cancer
, vol.111
, pp. 398-403
-
-
Varadhachary, A.1
Wolf, J.S.2
Petrak, K.3
-
28
-
-
0038410193
-
Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months
-
Ishii K, Takamura N, Shinohara M et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003; 25: 226-33.
-
(2003)
Hepatol Res
, vol.25
, pp. 226-233
-
-
Ishii, K.1
Takamura, N.2
Shinohara, M.3
-
29
-
-
0037855837
-
Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein
-
Nozaki A, Ikeda M, Naganuma A et al. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 2003; 278: 10 162 -73.
-
(2003)
J Biol Chem
, vol.278
, pp. 162-173
-
-
Nozaki, A.1
Ikeda, M.2
Naganuma, A.3
-
30
-
-
0035422262
-
Characterization of pseudotype VSV possessing HCV envelope proteins
-
Matsuura Y, Tani H, Suzuki K et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001; 286: 263-75.
-
(2001)
Virology
, vol.286
, pp. 263-275
-
-
Matsuura, Y.1
Tani, H.2
Suzuki, K.3
-
31
-
-
15944412810
-
Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication
-
Tamura K, Oue A, Tanaka A et al. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. Microbes Infect 2005; 7: 29-40.
-
(2005)
Microbes Infect
, vol.7
, pp. 29-40
-
-
Tamura, K.1
Oue, A.2
Tanaka, A.3
-
32
-
-
2342646131
-
A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load
-
Hirashima N, Orito E, Ohba K et al. A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol Res 2004; 29: 9-12.
-
(2004)
Hepatol Res
, vol.29
, pp. 9-12
-
-
Hirashima, N.1
Orito, E.2
Ohba, K.3
-
33
-
-
23944467709
-
Randomized placebo-controlled trial of interferon α-2b plus ribavirin with and without lactoferrin for chronic hepatitis C
-
Ishibashi Y, Takeda K, Tsukidate N et al. Randomized placebo-controlled trial of interferon α-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 2005; 32: 218-23.
-
(2005)
Hepatol Res
, vol.32
, pp. 218-223
-
-
Ishibashi, Y.1
Takeda, K.2
Tsukidate, N.3
|